Viralgen and Axovia are set to form a partnership to progress the development and manufacturing of gene therapy for retinal ...

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

While the company is prioritizing RJVA-001 and a lead program in obesity, it's pausing some R&D efforts and laying off 17 percent of its workforce.

The companies will work together by using the codon-optimized BBS1 AAV9 vector to minimize the vision loss caused by the ...

A new, streamlined AAV purification process that is both universal and scalable could ease commercialization constraint.

After spending years developing its endoscopic device treatment for patients with Type 2 diabetes, Fractyl Health is now ...

Genethon & Eukarÿs enter strategic partnership to develop a breakthrough technology to reduce the biomanufacturing cost of gene therapies: Evry, France Friday, January 24, 2025, ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

New Vericheck ddPCR Empty-Full Capsid Kits for AAV Serotypes 2 and 8 Provide Precise Measurement of Viral Titer and Capsid ...

With permission from a data safety monitoring committee, the firm will begin treating a second cohort with AMT-162 in the EPISOD1 trial in early 2025.

Viralgen and Axovia Therapeutics are partnering to develop and manufacture a gene therapy for the treatment of retinal ...